AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04238143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Stromal Vascular Fraction (tSVF) Arm 2
Description: Harvesting subcutaneous tSVF with sterile, disposable microcannula system
Study NCT04238143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP Concentrate Arm 2
Description: Preparation of PRP Concentrate via sterile Terumo-Harvest System
Study NCT04238143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cellular Stromal Vascular Fraction (cSVF) Arm 2
Description: Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)
Study NCT04238143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cellular Stromal Vascular Fraction (cSVF) Arm 3
Description: Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)
Study NCT04238143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline (IV Solution)
Description: Suspension of cSVF in 500 cc Sterile Normal Saline (IV Solution)
Study NCT02728583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Margarine enriched with plant sterols and fish oil
Study NCT02728583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo margarine
Study NCT04083469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Led Peer-Elected Intervention
Description: The intervention will be given to students by a peer opinion leader that the students in the audience elected. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
Study NCT04083469 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adult-Led Intervention
Description: The intervention will be given to students by an adult. The intervention is a version of CATCH My Breath curriculum that has been modified to match the Peer-Led Intervention curriculum but is able to be administered by an adult.
Study NCT03621293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modulation of Inspired Fraction of Oxygen (FiO2)
Description: In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient.
Study NCT03621293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modulation of Inspired Fraction of Oxygen (FiO2)
Description: In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient.
Study NCT00675506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone releasing hormone (GHRH) 1-44
Description: 2-mg sub-cutaneous injections once daily for 12 months
Study NCT00675506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2-mg sub-cutaneous injections once daily for 12 months
Study NCT02132533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.
Study NCT02132533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.
Study NCT02132533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual evaluation, monitoring and care for women with preterm labor.
Study NCT01183650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg, administered orally, daily for 10 days
Study NCT00299195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac
Description: Sulindac 150 mg po bid x 24 weeks
Study NCT00299195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid x 24 weeks
Study NCT03097003 — intervention group
Intervention type: DRUG
Intervention: Apremilast
Description: Psoriasis patients treated with Otezla® (Apremilast) in Belgium
Study NCT01306175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin plus BI 10773
Description: Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
Study NCT01306175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin 0.5 mg as single dose
Study NCT04435392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Cream
Description: Subjects in each group were scheduled to give the drug for 8 weeks.
Study NCT04435392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04435392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00786201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48
Study NCT00786201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 888 1 mg/kg
Description: IV infusion every 4 weeks, from Week 0 through Week 48
Study NCT00786201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 888 5 mg/kg
Description: IV infusion every 4 weeks, from Week 0 through Week 48
Study NCT00786201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 888 15 mg/kg
Description: IV infusion every 4 weeks, from Week 0 through Week 48
Study NCT02707419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Video of the exercises
Study NCT02707419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: video of nature scenes
Study NCT02707419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Mobilization, exercises and transfer practice.
Study NCT02707419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Mobilization, exercises and transfer practice.
Study NCT04136652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch
Description: women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
Study NCT04136652 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch
Description: women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
Study NCT04175418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Program
Description: The exercise program in this group includes aerobic (walking) training and exercises to strengthen the upper and lower extremities and trunk muscles.
Study NCT04175418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Education Program
Description: The exercise program in this group includes aerobic (walking) training and home exercises to strengthen the upper and lower extremities and trunk muscles.
Study NCT02125123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement and Counseling
Description: Ready-to-feed nutritional supplement and dietary counseling
Study NCT02125123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Dietary counseling
Study NCT04083469 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer-Led Non-Elected Intervention
Description: The intervention will be given to students by a peer opinion leader that was elected by other students. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
Study NCT03868748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-arbutin
Description: Beta-arbutin capsules
Study NCT03868748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules containing non-medicinal ingredients
Study NCT03868748 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules containing non-medicinal ingredients
Study NCT00704444 — intervention group
Intervention type: DRUG
Intervention: Ezetimibe
Description: Ezetimibe, 10-mg tablets
Study NCT00704444 — intervention group
Intervention type: DRUG
Intervention: Ezetimibe + other lipid-lowering medication(s)
Description: Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
Study NCT00810446 — intervention group
Intervention type: DRUG
Intervention: rifabutin
Description: Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.~3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily..
Study NCT02688998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: venous access PORT or PICC
Description: Participants will receive a venous access prior to starting chemotherapy
Study NCT01210677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone 0.5 mg/Kg orally per day for 3 months
Study NCT01210677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 0.5 mg/Kg orally per day for 3 months
Study NCT03963050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The ET program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.
Study NCT00211237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon Kyphoplasty
Description: Ballon Kyphoplasty is a minimally invasive technique aimed at reduction of VCFs using KyphX® Inflatable Bone Tamps followed by fracture fixation with KyphX® HV-R™ Bone Cement.
Study NCT00211237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Surgical Management
Description: Non-surgical treatment includes, but is not limited to, the following: back brace, pain medication, physical therapy, walking aids, bed rest, and radiation treatment.
Study NCT00493337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: advanced adherence counseling+reminder
Study NCT03030105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPN14770 placebo
Description: placebo
Study NCT03963050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training + Cognitive Training
Description: ET: The intervention program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.~CT: The intervention program will be configured as a cognitive rehabilitation and mainly memory rehabilitation: the participants will be trained in practicing restorative and compensatory mnemonic techniques, such as visual imagery, face-name association, calendar, notes and prompts.
Study NCT03963050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: NO changes in lifestyle
Study NCT03581734 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Polio Vaccine
Description: OPV is a mixture of live attenuated poliovirus strains of each of the three serotypes, selected by their ability to mimic the immune response following infection with wild polioviruses, but with a significantly reduced incidence of spreading to the central nervous system.
Study NCT03581734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine
Description: OPV is a mixture of live attenuated poliovirus strains of each of the three serotypes, selected by their ability to mimic the immune response following infection with wild polioviruses, but with a significantly reduced incidence of spreading to the central nervous system.
Study NCT03030105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: comparator
Study NCT03581734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Cholera Vaccine
Description: Bivalent, Killed, Whole Cell Oral Cholera Vaccine
Study NCT03581734 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cholera Vaccine
Description: Bivalent, Killed, Whole Cell Oral Cholera Vaccine
Study NCT02197286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: One capsule containing 4,000 IU of Cholecalciferol, per day
Study NCT02197286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of a single gelatin placebo capsule.
Study NCT05860439 — intervention group
Intervention type: PROCEDURE
Intervention: Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)
Description: Patients previously treated were reassessed for long-term follow-up.
Study NCT00875199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Prize-based contingency management for weight loss
Study NCT00875199 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight loss manual-guided individual therapy sessions
Description: once weekly counseling session with research staff
Study NCT03030105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: comparator
Study NCT03030105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil placebo
Description: placebo
Study NCT02389790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303
Study NCT00282906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hybrid PET-CT imaging system
Description: 15 mCi of FDG
Study NCT03676296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Puerarin
Description: Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks
Study NCT03676296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puerarin
Description: Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks
Study NCT03676296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
Study NCT03676296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
Study NCT02656290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards Pericardial Aortic Bioprosthesis Model 11000A
Description: Edwards Aortic Bioprosthesis Model 11000A in the pulmonary position; a trileaflet bioprosthesis comprised of bovine pericardium
Study NCT02852200 — intervention group
Intervention type: OTHER
Intervention: SEGAm
Study NCT01780402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand feeding techniques
Description: Direct hand feeding technique: When the feeding assistant holds the object (e.g., fork, spoon, cup) intended to provide food or fluids to the PWD without any active involvement on the part of the PWD.~Hand-over-hand feeding technique: Occurs when the PWD is holding the object (e.g., fork, spoon, cup) in an attempt to feed/ drink for themselves. If the PWD has trouble with this activity, the feeding assistant puts his or her hand over the hand of the PWD, in an effort to guide/ support/ assist the PWD with the activity.~Hand-under-hand feeding technique: Occurs when the feeding assistant holds the object (e.g., fork, spoon, cup) and places the PWD hand over the top of their hand; therefore, the feeding assistants hand is under the hand of the PWD in a more supportive position.
Study NCT02584127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high reinforcement cessation program
Description: Six-step, self-administered, internet smoking cessation program with high reinforcement.
Study NCT02584127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low reinforcement cessation program
Description: Six-step, self-administered, internet smoking cessation program with low reinforcement.
Study NCT00346047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corresponding placebo is applied for 12weeks
Study NCT00346047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal System
Description: Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
Study NCT00251303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Active drug put into 10-mg capsules by NIH Clinical Center Pharmacy. Matched placebo capsules were also prepared by NIH Clinical Center Pharmacy. Dose up to 120 mg daily, divided into bid dosages.
Study NCT00251303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules matched active drug in appearance.
Study NCT03007290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring
Description: Therapeutic drug monitoring for colistin
Study NCT04560283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal gel HYALOGYN®
Description: Vaginal gel HYALOGYN® (HYDEAL-D® 2%; Fidia Farmaceutici, Abano Terme, Italy) every 3 days up for 12 consecutive weeks
Study NCT04560283 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expectant management
Description: Expectant management for 12 consecutive weeks
Study NCT00632684 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interviews with a single treatment planning session
Description: Participants in Phase 1 will attend four 90-minute interviews over 4 months. During interviews, participants will be asked about their experiences caring for their relatives, physical and emotional well-being, and ideas on helpful types of assistance. Participants will also receive information about programs and services that may help them carry out caregiving activities.
Study NCT00632684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive treatment model
Description: The adaptive treatment model will include up to ten 60- to 75-minute planning sessions. The sessions will focus on psychosocial issues and will be tailored to participants' specific risk factors.
Study NCT02429388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Administration of spironolactone 25-50mg orally twice daily for two days and subsequently titrated upto 100mg twice daily with daily serum potassium monitoring. Spironolactone will continue until patient is euvolemic and appropriate for discharge. Titration of loop diuretics in this arm will not be escalated.
Study NCT00865917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta-blocker (Metoprolol)
Description: Metoprolol 95 mg once per day